Stocks · News reference
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The company, which provides blood management systems, is positioned in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential near-term stock price appreciation.
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.